Diagnostic Value of Peripheral Blood miR-374b-5p in Patients with Prostate Cancer

Pang, C.C.; Song, Xiaojing; Fu, Chunlong; Zhang, Yaoguang; Zhang, Yaqun; Liu, Ming

doi:10.7754/clin.lab.2019.190620

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased levels of miR-374b-5p in peripheral blood were proposed as a potential biomarker by Pang et al [166]. The study recruited samples from PCa (n = 42) and BPH (n = 42) patients, as well as healthy (n = 42) controls and the levels of miR-374b-5p measured.…”

Section: The Diagnostic and Prognostic Power Of Mirnas In Prostate Camentioning

confidence: 99%

miRNAs as Therapeutic Tools and Biomarkers for Prostate Cancer

Arrighetti

Beretta

2021

Pharmaceutics

View full text Add to dashboard Cite

Prostate cancer (PCa) is the fifth cause of tumor-related deaths in man worldwide. Despite the considerable improvement in the clinical management of PCa, several limitations emerged both in the screening for early diagnosis and in the medical treatment. The use of prostate-specific antigen (PSA)-based screening resulted in patients’ overtreatment and the standard therapy of patients suffering from locally advanced/metastatic tumors (e.g., radical prostatectomy, radiotherapy, and androgen deprivation therapy) showed time-limited efficacy with patients undergoing progression toward the lethal metastatic castration-resistant PCa (mCRPC). Although valuable alternative therapeutic options have been recently proposed (e.g., docetaxel, cabazitaxel, abiraterone, enzalutamide, and sipuleucel-T), mCRPC remains incurable. Based on this background, there is an urgent need to identify new and more accurate prostate-specific biomarkers for PCa diagnosis and prognosis and to develop innovative medical approaches to counteract mCRPC. In this context, microRNA (miRNAs) emerged as potential biomarkers in prostate tissues and biological fluids and appeared to be promising therapeutic targets/tools for cancer therapy. Here we overview the recent literature and summarize the achievements of using miRNAs as biomarkers and therapeutic targets/tools for fighting PCa.

show abstract

Section: The Diagnostic and Prognostic Power Of Mirnas In Prostate Camentioning

confidence: 99%

miRNAs as Therapeutic Tools and Biomarkers for Prostate Cancer

Arrighetti

Beretta

2021

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…At the same time, miRNA in serum can be stably present and can be obtained by non-invasive methods ( 16 ), as well as requiring only simple techniques such as quantitative reverse transcription-polymerase chain reaction (qRT-PCR) to detect its expression level ( 17 ). Much research has demonstrated the potential of miRNAs to be a screening biomarker for PCa ( 18 , 19 ).…”

Section: Introductionmentioning

confidence: 99%

The value of a panel of circulating microRNAs in screening prostate cancer

Sun,

Lu,

et al. 2024

Transl Cancer Res

View full text Add to dashboard Cite

Background Prostate cancer (PCa) remains a worldwide public health problem that poses a serious threat to the health of men worldwide. Many studies have found that microRNA (miRNA) in serum has the potential to be a biomarker for cancer screening. Our study was conducted to investigate the value of serum miRNAs in PCa screening. Methods We selected 12 miRNAs from past studies for its association with PCa. We checked the expression levels of these miRNAs in the serum of 112 PCa patients and 112 healthy controls in a two-stage experiment. We plotted the receiver operating characteristic curve of miRNAs in the validation stage and constructed a four-miRNA panel with the highest diagnostic value using stepwise logistic regression. We also predicted the target genes with these four miRNAs through online databases and performed Gene Ontology functional annotation and pathway analysis. Results The results showed that six miRNAs (miR-429, miR-10a-5p, miR-183-5p, miR-181a-5p, miR-1231, miR-129-5p) were abnormally expressed in the serum of PCa patients. We used four of these miRNAs including miR-1231, miR-10a-5p, miR-429 and miR-129-5p to construct a combination of miRNAs with high specificity and sensitivity in screening PCa (area under the curve =0.878). Bioinformatics analysis showed that the genes targeted by these miRNAs can be linked to the development of PCa. Conclusions Our study detected and identified a set of miRNAs that serves as screening marker for PCa, which may assist in early diagnosis and treatment of PCa.

show abstract

“…At the same time, miRNA in serum can be stably present and can be obtained by non-invasive methods (13), requiring only simple techniques such as qRT-PCR to detect its expression level (14). Much research has demonstrated the potential of miRNAs to be a screening biomarker for prostate cancer (15,16).…”

Section: Introductionmentioning

confidence: 99%

The value of a group of serum miRNAs in screening prostate cancer

Sun

et al. 2022

Preprint

View full text Add to dashboard Cite

Background Prostate cancer remains a worldwide public health problem that poses a serious threat to the health of men worldwide. Many studies have found that miRNA in serum has the possible to be a biomarker for cancer. Our study was conducted to investigate the valuation of serum miRNAs in prostate cancer screening. Methods We selected 12 miRNAs from past studies associated with prostate cancer. We checked the expression levels of these miRNAs in the serum of 112 prostate cancer patients and 112 healthy controls in a two-stage experiment. We plotted the receiver operating characteristic curve of miRNAs in the validation stage and constructed a four-miRNA panel with the highest diagnostic value using stepwise logistic regression. We also predicted the target genes for these four miRNAs through online databases and performed Gene Ontology functional annotation and pathway analysis. Results The results showed that 6 miRNAs (miR-429, miR-10a-5p, miR-183-5p, miR-181a-5p, miR-1231, miR-129-5p) were abnormally expressed in the serum of prostate cancer patients. We used four of these miRNAs including miR-1231, miR-10a-5p, miR-429 and miR-129-5p to construct a combination of miRNAs with high specificity and sensitivity in screening prostate cancer (area under the curve (AUC) = 0.878). Bioinformatic analysis has shown that the genes targeted by these miRNAs can be linked to the development of cancer. Conclusions Our study detected and identified a set of miRNAs that serve as screening markers for prostate cancer, which may assist in early diagnosis and treatment of prostate cancer.

show abstract

Diagnostic Value of Peripheral Blood miR-374b-5p in Patients with Prostate Cancer

Cited by 3 publications

References 0 publications

miRNAs as Therapeutic Tools and Biomarkers for Prostate Cancer

miRNAs as Therapeutic Tools and Biomarkers for Prostate Cancer

The value of a panel of circulating microRNAs in screening prostate cancer

The value of a group of serum miRNAs in screening prostate cancer

Contact Info

Product

Resources

About